The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-d-aspartate and D1 receptor binding in rats

Neuroscience

Volumn 165, Issue 2, 2010, Pages 492-499

  Toua, C ^a   Brand, L ^a   Moller M ^a   Emsley, R A ^b   Harvey, B H ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

clozapine versus haloperidol; D1 receptor; frontal cortex; NMDA receptor; schizophrenia; social isolation rearing

Indexed keywords

CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; GLUTAMIC ACID; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL HOUSING; ARTICLE; BINDING AFFINITY; CHILD REARING; CONTROLLED STUDY; EXPERIMENTAL MODEL; FRONTAL CORTEX; LIFE EVENT; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; SCHIZOPHRENIA; SOCIAL ISOLATION;

AGING; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; FRONTAL LOBE; HALOPERIDOL; MALE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SOCIAL ISOLATION;

EID: 71849098622     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.10.039     Document Type: Article

References (71)

1. Abekawa T., Ito K., and Koyama T. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol 374 (2006) 177-193
2. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., Hwang D.R., Keilp J., Kochan L., Van H.R., Gorman J.M., and Laruelle M. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22 (2002) 3708-3719
3. A receptors before and after the stress of predator exposure prevents lasting increases in anxiety-like behavior: implications for anxiety associated with posttraumatic stress disorder. Behav Neurosci 111 (1997) 435-449
4. Ahlenius S. Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol Toxicol 84 (1999) 193-196
5. Artaloytia J.F., Arango C., Lahti A., Sanz J., Pascual A., Cubero P., Prieto D., and Palomo T. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 163 (2006) 488-493
6. Ascher-Svanum H., Nyhuis A.W., Faries D.E., Kinon B.J., Baker R.W., and Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull 34 (2008) 1163-1171
7. Atkins M., Burgess A., Bottomly C., and Riccio M. Chlorpromazine equivalents: a concensus of opinion for both clinical and research applications. Psychiatr Bull 21 (1997) 224-226
8. Ayhan Y., Sawa A., Ross C.A., and Pletnikov M.V. Animal models of gene-environment interactions in schizophrenia. Behav Brain Res 204 (2009) 274-281
9. Bakshi V.P., Swerdlow N.R., and Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271 (1994) 787-794
10. Bast T., Zhang W., Feldon J., and White I.M. Effects of MK801 and neuroleptics on prepulse inhibition: re-examination in two strains of rats. Pharmacol Biochem Behav 67 (2000) 647-658
11. Beraki S., Kuzmin A., Tai F., and Ogren S.O. Repeated low dose of phencyclidine administration impairs spatial learning in mice: blockade by clozapine but not by haloperidol. Eur Neuropsychopharmacol 18 (2008) 486-497
12. Billard W., Ruperto V., Crosby G., Iorio L.C., and Barnett A. Characterization of the binding of [3H]-SCH23390, a selective D1 receptor antagonist ligand, in rat striatum. Life Sci 35 (1984) 1885-1893
13. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding. Anal Biochem 72 (1976) 248-254
14. Bressan R.A., Erlandsson K., Stone J.M., Mulligan R.S., Krystal J.H., Ell P.J., and Pilowsky L.S. Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-d-aspartate receptors in vivo. Biol Psychiatry 58 (2005) 41-46
15. Brink C.B., Clapton J.D., Eagar B.E., and Harvey B.H. Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies. J Neural Transm 115 (2008) 117-125
16. Castner S.A., Williams G.V., and Goldman-Rakic P.S. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287 (2000) 2020-2022
17. Castner S.A., and Williams G.V. Tuning the engine of cognition: a focus on NMDA/D1 receptor interactions in prefrontal cortex. Brain Cogn 63 (2007) 94-122
18. Chen L., and Yang C.R. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J Neurophysiol 87 (2002) 2324-2336
19. Crowe S.L., Movsesyan V.A., Jorgensen T.J., and Kondratyev A. Rapid phosphorylation of histone H2AX following ionotropic glutamate receptor activation. Eur J Neurosci 23 (2006) 2351-2361
20. Del Arco A., and Mora F. Dopamine release in the prefrontal cortex during stress is reduced by the local activation of glutamate receptors. Brain Res Bull 56 (2001) 125-130
21. Didriksen M., Skarsfeldt T., and Arnt J. Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. Psychopharmacology (Berl) 193 (2007) 225-233
22. du Bois T.M., and Huang X.F. Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. Brain Res Rev 53 (2007) 260-270
23. Emsley R., Rabinowitz J., Medori R., and Early Psychosis Global Working Group. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 89 (2007) 129-139
24. Feifel D., and Priebe K. The effects of subchronic haloperidol on intact and dizocilpine-disrupted sensorimotor gating. Psychopharmacology (Berl) 146 (1999) 175-179
25. Follesa P., and Ticku M.K. NMDA receptor upregulation: molecular studies in cultured mouse cortical neurons after chronic antagonist exposure. J Neurosci 16 (1996) 2172-2178
26. Gao X.M., Sakai K., Roberts R.C., Conley R.R., Dean B., and Tamminga C.A. Ionotropic glutamate receptors and expression of N-methyl-d-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 157 7 (2000) 1141-1149
27. Gessa G.L., Devoto P., Diana M., Flore G., Melis M., and Pistis M. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 22 (2000) 642-649
28. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156 (2001) 117-154
29. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., and Williams G.V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 174 (2004) 3-16
30. Gray J.A., and Roth B.L. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 33 (2007) 1100-1119
31. Guillin O., Abi-Dargham A., and Laruelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 78 (2007) 1-39
32. Hall F.S., Ghaed S., Pert A., and Xing G. The effects of isolation rearing on glutamate receptor NMDAR1A mRNA expression determined by in situ hybridization in Fawn hooded and Wistar rats. Pharmacol Biochem Behav 73 (2002) 185-191
33. Harvey B.H., Stein D.J., and Emsley R.A. The new-generation antipsychotics-integrating the neuropathology and pharmacology of schizophrenia. S Afr Med J 89 (1999) 661-672
34. Harvey B.H., Oosthuizen F., Brand L., Wegener G., and Stein D.J. Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus. Psychopharmacology 175 (2004) 494-502
35. Heidbreder C.A., Foxton R., Cilia J., Hughes Z.A., Shah A.J., Atkins A., Hunter A.J., Hagan J.J., and Jones D.N. Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation. Psychopharmacology (Berl) 156 (2001) 338-351
36. Heresco-Levy U. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 1113-1123
37. Holcomb H.H., Rowland L.M., and Tagamets M.A. Cognitive dysfunction in schizophrenia: glutamatergic hypoactivity and dopaminergic failure. Drug Discov Today Dis Mech 1 (2004) 435-439
38. Hu X.J., and Ticku M.K. Chronic ethanol treatment upregulates the NMDA receptor function and binding in mammalian cortical neurons. Brain Res Mol Brain Res 30 (1995) 347-356
39. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vockler J., Dikranian K., Tenkova T.I., Stefovska V., Turski L., and Olney J.W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283 (1999) 70-74
40. Javitt D.C., Shelley A.M., Silipo G., and Lieberman J.A. Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Arch Gen Psychiatry 57 (2000) 1131-1137
41. Kapur S., Arenovich T., Agid O., Zipursky R., Lindborg S., and Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 162 (2005) 939-946
42. Karlsson P., Farde L., Halldin C., and Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159 (2002) 761-767
43. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A., and CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64 (2007) 633-647
44. Keith V.A., Mansbach R.S., and Geyer M.A. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 30 (1991) 557-566
45. Kruse M.S., Prémont J., Krebs M.O., and Jay T.M. Interaction of dopamine D1 with NMDA NR1 receptors in rat prefrontal cortex. Eur Neuropsychopharmacol 19 (2009) 296-304
46. Kuroki T., Meltzer H.Y., and Ichikawa J. Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288 (1999) 774-781
47. Law A.J., and Deakin J.F. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 12 (2001) 2971-2974
48. Lidow M.S. General overview of contemporary antipsychotic medications. In: Lidow M.S. (Ed). Neurotransmitter receptors in actions of antipsychotic medications (2000), CRC Press LLC, Florida 17-31
49. Lidow M.S., Williams G.V., and Goldman-Rakic P.S. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol Sci 19 (1998) 136-140
50. Marder S.R., and Fenton W. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72 (2004) 5-9
51. McLean S.L., Idris N.F., Woolley M.L., and Neill J.C. D1-like receptor activation improves PCP-induced cognitive deficits in animal models: implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol 19 (2009) 440-450
52. McKinney M., and Raddatz R. Practical aspects of receptor binding. Curr Protoc Pharmacol 33 (2006) 1.3.1-1.3.42
53. Mu Q., Johnson K., Morgan P.S., Grenesko E.L., Molnar C.E., Anderson B., Nahas Z., Kozel F.A., Kose S., Knable M., Fernandes P., Nichols D.E., Mailman R.B., and George M.S. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (dar-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res 94 (2007) 332-341
54. Murray R.M. Neurodevelopmental schizophrenia: the rediscovery of dementia praecox. Br J Psychiatry 165 25 Suppl (1994) 6-12
55. Nel A., and Harvey B.H. Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine. Behav Pharmacol 14 (2003) 251-255
56. Ninan I., Jardemark K.E., and Wang R.Y. Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-d-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex. Neuropharmacology 44 (2003) 462-472
57. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., Someya Y., Sassa T., Sudo Y., Matsushima E., Iyo M., Tateno Y., and Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385 (1997) 634-636
58. Ossowska K., Pietraszek M., Wardas J., Nowak G., and Wolfarth S. Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn Schmiedebergs Arch Pharmacol 359 (1999) 280-287
59. Pei L., Lee F.J., Moszczynska A., Vukusic B., and Liu F. Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. J Neurosci 24 (2004) 1149-1158
60. Powell S.B., Zhou X., and Geyer M.A. Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res 204 (2009) 282-294
61. Prast H., and Philippu A. Nitric oxide as modulator of neuronal function. Prog Neurobiol 64 (2001) 51-68
62. Scott L., and Aperia A. Interaction between N-methyl-D-aspartic acid receptors and D1 dopamine receptors: an important mechanism for brain plasticity. Neuroscience 158 (2009) 62-66
63. Steinpresis R.E. The behavioral and neurochemical effects of phenyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res 74 (1996) 45-55
64. Swartz M.S., Stroup T.S., McEvoy J.P., Davis S.M., Rosenheck R.A., Keefe R.S., Hsiao J.K., and Lieberman J.A. What CATIE found: results from the schizophrenia trial. Psychiatr Serv 59 (2008) 500-506
65. Tarazi F.I., Florijn W.J., and Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology (Berl) 128 (1996) 371-379
66. Tarazi F.I., Baldessarini R.J., Kula N.S., and Zhang K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 306 (2003) 1145-1151
67. Tseng K.Y., and O'Donnell P. Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J Neurosci 24 (2004) 5131-5139
68. Turnock-Jones J.J., Jennings C.A., Robbins M.J., Cluderay J.E., Cilia J., Reid J.L., Taylor A., Jones D.N., Emson P.C., and Southam E. Increased expression of the NR2A NMDA receptor subunit in the prefrontal cortex of rats reared in isolation. Synapse 63 (2009) 836-846
69. Varty G.B., Braff D.L., and Geyer M.A. Is there a critical developmental "window" for isolation rearing-induced changes in prepulse inhibition of the acoustic startle response?. Behav Brain Res 100 (1999) 177-183
70. Weiss I.C., Di I.L., Feldon J., and Domeney A.M. Strain differences in the isolation-induced effects on prepulse inhibition of the acoustic startle response and on locomotor activity. Behav Neurosci 114 (2000) 364-373
71. Weiss I.C., and Feldon J. Environmental animal models for sensorimotor gating deficiencies in schizophrenia: a review. Psychopharmacology 156 (2001) 305-326